argenx SE (ARGX)
| Market Cap | 53.75B +48.6% |
| Revenue (ttm) | 5.32B +70.3% |
| Net Income | 1.72B +33.9% |
| EPS | 26.21 +39.8% |
| Shares Out | 62.54M |
| PE Ratio | 31.34 |
| Forward PE | 24.62 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 216,214 |
| Open | 861.00 |
| Previous Close | 882.56 |
| Day's Range | 855.87 - 870.31 |
| 52-Week Range | 596.01 - 953.58 |
| Beta | -0.02 |
| Analysts | Buy |
| Price Target | 1,079.55 (+23.94%) |
| Earnings Date | Jul 23, 2026 |
About ARGX
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave’s disease, myositis, Sjögren’s disease, system... [Read more]
Financial Performance
In 2025, argenx SE's revenue was $4.24 billion, an increase of 88.44% compared to the previous year's $2.25 billion. Earnings were $1.29 billion, an increase of 55.10%.
Financial StatementsAnalyst Summary
According to 24 analysts, the average rating for ARGX stock is "Buy." The 12-month stock price target is $1,079.55, which is an increase of 23.94% from the latest price.
News
Corning removed from ‘US 1 List’ at BofA
BofA is renewing Argenx (ARGX) for a new term following 52 weeks on the firm’s “US 1 List” while removing Corning (GLW). The US 1 List is a collection of…
Forte Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Forte Biosciences, Inc. - FBRX
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Forte...
ARGX Maintained by Wedbush -- Price Target Raised to $1050
ARGX Maintained by Wedbush -- Price Target Raised to $1050
First Tracks Biotherapeutics price target raised to $60 from $30 at Wedbush
Wedbush raised the firm’s price target on First Tracks Biotherapeutics to $60 from $30 and keeps an Outperform rating on the shares. Relevant for First Tracks Biotherapeutics (TRAX), Argenx (ARGX)…
Argenx price target raised to $1,050 from $1,000 at Wedbush
Wedbush raised the firm’s price target on Argenx (ARGX) to $1,050 from $1,000 and keeps an Outperform rating on the shares. The firm notes the company will acquire Forte Biosciences…
argenx SE To Acquire Forte Biosciences Transcript
argenx SE To Acquire Forte Biosciences Transcript
argenx Expands Immunology Pipeline with Forte Biosciences Acquisition
argenx Expands Immunology Pipeline with Forte Biosciences Acquisition
After Forte acquisition, H.C. Wainwright says First Tracks could be target
After Argenx (ARGX) announced a deal to acquire Forte (FBRX) for a price of $77 per share, a 43% premium to Friday’s share price and a total equity value of…
Forte Biosciences downgraded to In Line from Outperform at Evercore ISI
Evercore ISI downgraded Forte Biosciences (FBRX) to In Line from Outperform with a price target of $77, up from $69, after Argenx (ARGX) agreed to acquire Forte for $77 per…
argenx Strikes $2.2B Deal for Forte, Adds Autoimmune Drug FB102
argenex NASDAQ: ARGX said it has agreed to acquire Forte Biosciences in a transaction valued at approximately $2.2 billion in equity value, adding FB102, an anti-CD122 antibody being developed for aut...
ARGX Maintained by Baird -- Price Target Raised to $932
ARGX Maintained by Baird -- Price Target Raised to $932
M&A News: Forte Biosciences Shares Leap 40% After Argenx Seals $2.2B Immunology Deal
Shares in Forte Biosciences ($FBRX) were 40% healthier in pre-market trading today after it was bought by peer Argenx ($ARGX) for $2.2 billion. Multiple Autoimmune Conditions Dutch immunology innovati...
argenx SE Transcript: M&A announcement
The acquisition brings a first-in-class anti-CD122 antibody, FB102, into the immunology pipeline, targeting large unmet needs in vitiligo and celiac disease, with potential for broader autoimmune indications. The $2.2B cash deal leverages proven development and commercialization strategies to maximize impact and supports long-term growth ambitions.
argenx SE Press release: M&A announcement
argenx SE issued a press release on July 27, 2026, disclosing material business information to investors.
argenx SE Slides: M&A announcement
argenx SE has posted slides in relation to its latest quarterly earnings report, which was published on July 27, 2026.
Argenx price target raised to $932 from $867 at Baird
Baird raised the firm’s price target on Argenx (ARGX) to $932 from $867 and keeps a Neutral rating on the shares. The firm updated its model following Q2 results which…
Forte Biosciences (FBRX) Soars 39% on Acquisition by Argenx
Forte Biosciences (FBRX) Soars 39% on Acquisition by Argenx
Argenx (ARGX) to Acquire Forte Biosciences for $2.2 Billion
Argenx (ARGX) to Acquire Forte Biosciences for $2.2 Billion
argenx SE (ARGX) to Acquire Forte Biosciences (FBRX) for $2.2B
argenx SE (ARGX) to Acquire Forte Biosciences (FBRX) for $2.2B
Argenx to acquire Forte Biosciences for $77 per share in cash
Argenx (ARGX) and Forte (FBRX) announced that the companies have entered into a definitive agreement under which Argenx will acquire Forte Biosciences for $77 per share in cash, representing a…
Argenx To Acquire Forte For Approx. $2.2 Bln To Expand Immunology Pipeline; Forte Shares Soar
(RTTNews) - Argenx (ARGX), an immunology company, and Forte Biosciences, Inc. (FBRX),a clinical-stage biopharmaceutical company on Monday announced that they have entered into a definitive agreement u...
Argenx Acquires Forte Biosciences for $2.2 Billion, Expanding Pipeline
Argenx Acquires Forte Biosciences for $2.2 Billion, Expanding Pipeline
Argenx to Buy Forte Biosciences for $2.2 Billion
The deal to acquire the Nasdaq-listed Forte represents a 41% premium to its closing price on Friday.
Argenx to buy Forte Biosciences for about $2.2 billion
Belgian-Dutch immunology company argenx will buy Forte Biosciences to add experimental autoimmune drug FB102 to its portfolio, the company said on Monday.
argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class Anti-CD122 Antibody, FB102, to Its Immunology Pipeline
AMSTERDAM & DALLAS--(BUSINESS WIRE)--argenx (Euronext & Nasdaq: ARGX), a global immunology innovation company, and Forte Biosciences, Inc. (Nasdaq: FBRX) today announced that the companies have enter...